Altimmune, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
ALT Nasdaq 2836 altimmune.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Altimmune, Inc.

Altimmune to Participate in the H.C. Wainwright 8th Annual MASH Virtual Conference - Oct 1st, 2024 11:30 am
Altimmune Completes Enrollment in Phase 2b IMPACT Trial of Pemvidutide in Metabolic Dysfunction-Associated Steatohepatitis (MASH) - Sep 30th, 2024 11:30 am
CORRECTION – Altimmune Presents Results of a Phase 2 MRI-Based Body Composition Sub-Study at 60th Annual Meeting of the European Association for the Study of Diabetes - Sep 10th, 2024 5:09 pm
Altimmune Presents Results of a Phase 2 MRI-Based Body Composition Sub-Study at 60th Annual Meeting of the European Association for the Study of Diabetes - Sep 10th, 2024 11:45 am
Altimmune Announces Oral Presentation of Pemvidutide Clinical Data at 60th Annual Meeting of the European Association for the Study of Diabetes - Sep 3rd, 2024 11:30 am
Altimmune First Half 2024 Earnings: Revenues Beat Expectations, EPS Lags - Aug 10th, 2024 1:03 pm
Altimmune Announces Second Quarter 2024 Financial Results and Provides a Business Update - Aug 8th, 2024 11:00 am
CytoSorbents to Report Second Quarter 2024 Operating and Financial Results - Aug 7th, 2024 11:00 am
With 56% ownership, Altimmune, Inc. (NASDAQ:ALT) boasts of strong institutional backing - Aug 1st, 2024 12:47 pm
Altimmune to Report Second Quarter 2024 Financial Results and Provide Business Update on August 8, 2024 - Aug 1st, 2024 11:30 am
Altimmune Announces Publication of Clinical Study of Pemvidutide in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in Journal of Hepatology - Jul 25th, 2024 11:30 am
Altimmune to Participate at Leerink Partners Therapeutics Forum - Jul 2nd, 2024 11:30 am
Altimmune Mourns Passing of Chief Financial Officer, Richard Eisenstadt - Jun 26th, 2024 11:30 am
Crypto under pressure, Good Buy or Goodbye: Market Domination - Jun 24th, 2024 10:02 pm
Altimmune reports positive results in weight-loss drug trial - Jun 24th, 2024 7:52 pm
Altimmune Presents Data from Phase 2 MOMENTUM Trial of Pemvidutide in Obesity during Oral Presentation at the American Diabetes Association’s 84th Scientific Sessions - Jun 23rd, 2024 5:45 pm
Altimmune Presents Data on the Effect of Pemvidutide on Cardioinflammatory Lipids during Oral Presentation at American Diabetes Association’s 84th Annual Scientific Sessions - Jun 22nd, 2024 8:45 pm
Altimmune (NASDAQ:ALT) Is In A Good Position To Deliver On Growth Plans - Jun 21st, 2024 3:36 pm
Altimmune to Participate in the Piper Sandler 2nd Annual Virtual Obesity Investor Day to Discuss ADA Takeaways - Jun 20th, 2024 11:30 am
Altimmune Announces Oral Presentations of Pemvidutide Clinical Data at Upcoming American Diabetes Association’s Scientific Sessions - Jun 18th, 2024 11:30 am